CHEK1 and acute lymphoblastic leukemia: The combination of CHK1 inhibition with other targeted agents as well as immunotherapies against ALL are likely to be more promising than their combination with cytotoxic agents given the hematologic toxicity and the chemo resistant nature of the relapsed ALL.